Abcam, ab313336, Anti-Calcitonin receptor/CT-R antibody [EPR27455-47] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal Calcitonin receptor/CT-R antibody. Carrier free. Suitable for IHC-P, WB and reacts with Rat, Transfected cell lysate - Rat samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR27455-47,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Rat,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Calcitonin receptor (CT-R) is a protein that mechanically binds calcitonin a hormone involved in regulating calcium levels. Another known name is Salmon Calcitonin Receptor. The receptor has a mass approximately 70 kDa and is expressed in various tissues including kidney osteoclasts and the central nervous system. The receptor is a critical part of calcium-phosphate homeostasis facilitating the actions of calcitonin across different physiological systems in the body.
Biological function summary
CT-R serves a significant role in bone metabolism and mineral homeostasis. It participates in the inhibition of osteoclast-mediated bone resorption which is an important process in maintaining bone density. Although CT-R functions independently interactions with other hormones like parathyroid hormone and vitamin D highlight its importance in a larger network of bone health. The receptor contributes to reducing blood calcium levels by decreasing calcium release from bones and enhancing renal calcium excretion.
Pathways
CT-R is actively involved in the cyclic adenosine monophosphate (cAMP) and phosphoinositide signaling pathways essential for mediating cellular responses. Through these pathways CT-R closely associates with the related protein Calcitonin Gene-Related Peptide (CGRP) which shares some signaling components and effects on targeted cells. These pathways highlight the mechanistic basis for CT-R's roles in regulating calcium and phosphate metabolism.
CT-R has connections to osteoporosis and paget's disease. These conditions involve impaired bone metabolism where CT-R activity—or lack of activity—contributes to pathogenesis. The receptor's relationship with the proteins parathyroid hormone and CGRP suggests its indirect involvement in disease progression since these proteins also modulate bone health and are potential therapeutic targets for treating such bone disorders.